A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to patients with bile duct cancers testing positive for HER2 or with mutated HER2 in research from Japan reported at the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium held in Barcelona, Spain.
In the SGNTUC-019 Phase II basket study of 217 patients, who had a variety of previously treated solid tumors with HER2 overexpressed, amplified, or mutated, a combination of tucatinib with trastuzumab brought significant clinical responses among those with biliary tract tumors in addition to those with breast cancer.
Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Intentionally Disturbing
Join me on this podcast as I navigate the murky waters of human behavior, current events, and personal anecdotes through in-depth interviews with incredible people—all served with a generous helping of sarcasm and satire. After years as a forensic and clinical psychologist, I offer a unique interview style and a low tolerance for bullshit, quickly steering conversations toward depth and darkness. I honor the seriousness while also appreciating wit. I’m your guide through the twisted labyrinth of the human psyche, armed with dark humor and biting wit.